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Genetic defects affecting acyl-CoA dehydrogenases (ACAD)—key enzymes in the degradation of fatty acids and branched chain amino
acids—are increasingly recognized as being more widespread than originally thought. For the medium-chain acyl-CoA dehydrogenase
(MCAD), the K304E mutation is the most common genetic defect among Caucasian populations. The effect of substrate or substrate analog
binding on the stability of wild-type MCAD and isovaleryl-CoA dehydrogenase (i3VD) and their genetic mutants (K304E- and T168A-
MCAD and A282V-i3VD) is examined. Binding to the mutant ACADs is generally c 10-fold weaker compared to wild-type proteins.
Thermal stability of wt-MCAD (melting point c 53.6 jC) is significantly higher compared to wt-i3VD (c 49.3 jC). With the exception of
the A282V-i3VD mutant, a high degree of stabilization (5–11 jC) is induced by conversion into the reduced enzyme form complexed with
product. The results are discussed based on the 3D-structures of the enzymes, and it is concluded that in the case of K304E-MCAD thermal
stability as such is not a major contribution to the clinical phenotype. With the T168A-MCAD and A282V-i3VD mutants, however, the
diminished thermal stability and minor stabilization by ligands must be regarded as an important factor contributing to the manifestation of
the disease.
D 2004 Elsevier B.V. All rights reserved.Keywords: Acyl-CoA dehydrogenase; Enzyme stability; Conformational disease
1. Introduction different types of fatty acids linked to CoA [1–3]. TwoAcyl-CoA dehydrogenases form a family of FAD-depen-
dent enzymes that currently encompass nine members. They
catalyze the same chemical step, the a, h-desaturation of
acyl-CoA conjugates, and differ in their specificity for0925-4439/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
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2 For the abbreviations of enzymes, see Table 1.subfamilies can be differentiated. The first, comprising four
members (VLCAD1, ACAD9/VLCAD2, MCAD, and
SCAD), acts on ‘‘straight chain’’ substrates that are degrad-
ed sequentially in the h-oxidation cycle [2]. The second
group has five members (LCAD, iBD, i2VD, i3VD, and
GD) that are active against branched chain substrates, or the
dicarboxylic acid glutarate, degradation product of glutamic
acid, in the case of GD [3]. These enzymes and abbrevia-
tions derived from their substrate preferences that have been
studied recently are listed in Table 1. It should be stated that
there can be considerable overlap in the activity profiles and
that the mentioned subdivisions can be only orientative.
The best-studied member of the first subfamily is medi-
um-chain acyl-CoA dehydrogenase (MCAD), an enzyme
Table 1
List of abbreviations of enzymes acting in the a,h-dehydrogenation of fatty acid acyl-CoA conjugates
‘‘Trivial’’ names of ACADs (alternative names) Substrate type Other/alternative abbreviations Abbreviation
Acyl-CoA dehydrogenase Generic ACAD
Short chain acyl-CoA dehydrogenase
(butyryl-CoA dehydrogenase)
Straight SCADH SCAD
Medium-chain acyl-CoA dehydrogenase Straight MCADH MCAD
Very long chain acyl-CoA dehydrogenase Straight VLCAD, VLCADH VLCAD1
(Very long chain acyl-CoA dehydrogenase)a Straight/branched
(unsaturated)
ACAD-9 VLCAD2a
Long chain acyl-CoA dehydrogenase Straight/branched LCADH LCAD
Isobutyryl-CoA dehydrogenase Branched ACAD-8 iBD
Iso(3)valeryl-CoA dehydrogenase Branched iVD i3VD
Iso(2)valeryl-CoA dehydrogenase
(‘‘short, branched chain’’ acyl-CoA dehydrogenase),
(2-methylbutyryl-CoA dehydrogenase)
Branched SBCAD, 2mBD ACADSB i2VD
Glutaryl-CoA dehydrogenase (modified) GDH GD
The first five members are thought to be selective for straight chain acyl-CoA substrates, the latter four for branched or modified ones. The newly formulated
terms base, respectively, on the differences in activities that have been recognized recently [7].
a Unpublished data (Vockley, J. et al.), suggest that this enzyme is active towards substrates with a chain longer than that of VLCAD1 and acts also on
unsaturated substrates.
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spectrum of substrate utilization [3], is present at significant
quantities in many organs [5], and the three-dimensional
structure has been elucidated [6]. This enzyme gained
medical relevance upon the discovery, some two decades
ago, of an inherited genetic defect, which is among the most
frequent ones in humans of northern European descent [2].
A common point mutation causing a K304E replacement is
found in 90% of mutant alleles from MCAD deficient
patients, and has been associated with heterogeneous clin-
ical symptoms and cellular defects [2,8]. This amino acid is
located in the long alpha helix H that forms part of the
interface between subunits of the MCAD homotetramer and
leads to impaired folding [8,9], low expression of mature
protein, instability, and a modified activity spectrum [8].
Another mutation in the MCAD gene in patients with
MCAD deficiency leads to an amino acid replacement of
threonine 168 to alanine. Threonine 168 is located in the
active site of the enzyme in contact with the FAD cofactor
and forms a hydrogen bond with the flavin N(5) [10]. The
mutant enzyme is stable but only partially active when
expressed in heterologous systems. As is seen with the
K304E mutation, patients with the T168A mutation present
with heterogeneous symptoms [11]. i3VD is the best-studied
member of the subfamily involved in the catabolism of
amino acids [12]; its biochemical properties have been
addressed, and its 3D-structure is known [13]. Several
mutations leading to amino acid substitutions have been
identified in patients with the clinical disorder isovaleric
acidemia (IVA), caused by deficiency of i3VD activity. This
disorder can cause a wide spectrum of clinical symptoms,
and this may at least in part be related to the level of stability
of the mutant enzyme [14]. The most functional i3VD
mutants reported are A282V, V342A, and R382L, each of
which retains significant partial activity compared to wild-
type enzyme when produced in an E. coli system. [14].In a general sense, many of the mutations discovered in
patients with enzyme defects in mitochondrial h-oxidation
can be classified under the term ‘‘conformational diseases,’’
with decreased folding of the mutant protein to a functional
form under conditions of physiologic stress [15]. This
correlates well with the observation that clinical symptoms
in these disorders are often exacerbated by otherwise
unrelated underlying illness, especially when associated
with fever. In this regard, MCAD and i3VD are appropriate
candidates for studying in a semiquantitative manner, the
extent to which mutations leading to amino acid substitu-
tions affect protein folding and stability. Study of these
processes will provide a better understanding of the effects
of physiologic stress on mutant proteins in patients with
these disorders, lead to the identification of amino acid
motifs and physiologic conditions that help stabilize mutant
proteins, and ultimately, the development of therapies
designed to improve their stability. In this report, we present
thermal stability studies of wild-type, K304E-, and T168A-
MCAD enzymes, and wild-type and A282V-i3VD enzymes.2. Materials and methods
2.1. Materials
Desalting C18 cartridges (Sep-Pak Vac 35 cc C18 car-
tridges) were from Waters. Hexyl isocyanate from ACROS
and isopropyl isocyanate from Aldrich, all other chemicals
from Sigma.
2.2. Preparation and purification of acyl-CoA derivatives
Octanoyl-CoA, isovaleryl-CoA, 2-aza-iC5-CoA, and 2-
azaoctanoyl-CoA were synthesized by published proce-
dures [16]. The crude products were desalted using C18
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of CoAs with 80% methanol). Purity of the products was
analyzed by HPLC (Kroma system 2000) using 5 mM
potassium phosphate buffer, pH 6.0, (pump A) and a
gradient from 5% to 35% MeOH (pump B) over 20 min.
The 2-azaoctanoyl-CoA and 2-aza-iC5-CoA eluted at 16.2
and 11.9 min, respectively. Purities were 94% and 92%,
respectively. Concentrations were determined using
e260 = 20 mM
 1 cm 1 for saturated acyl-CoAs [17] and
e258 = 16 mM
 1 cm 1 for 2-aza-acyl-CoAs.
2.3. Purification of enzymes and mutants
wt-MCAD [8], K304E- [8], T168A-MCAD [10], wt-
i3VD [14,18], and A282V-i3VD were heterologously
expressed in E. coli and purified as described in the
indicated literature.
2.4. Thermal unfolding
Thermal unfolding of MCAD, i3VD, and their mutants
was monitored in 0.1-cm cuvettes using a Jasco J-500
spectropolarimeter at 222 nm. The cuvette was placed in a
thermostatted cell holder. The temperature was raised con-
tinuously in general from 3 to 93 jC (or as specified) at a
heating rate of 1.0 jC/min. In all experiments, the enzyme
concentration was c 5 AM in 25 mM potassium phosphate,
pH 7.5. Substrate stock solutions were prepared in the same
buffer, and added at the indicated final concentration.
2.5. Data analysis
The experimental data (h222 = f (T )) were converted to
plots of FD = f (T ) assuming that the ellipticities of the native
and denatured state depend linearly on the temperature
according to: hN = hN,0 + aN T (1) and hD = hD,0 + aD T
(2), respectively. hN,i and ai are the coefficients of the linearScheme 1. Equilibria present in a system containing ACADs and substrates (adap
probably consists of several steps involving not shown intermediates that lead to
chemical oxidoreduction equilibrium linking (A) to (B), the complex of reduced en
of two species in rapid equilibrium (not shown) and is characterized by a green to
(P-CoA) from (B) (step c) is thermodynamically very unfavorable (Kds < 0.1 AM
ACADred. The latter, in turn, can bind excess substrate (step e), while free product
with ACAD will thus lead to a mixture of species that are linked by rapid or slow
depend on temperature, on the concentrations of S-CoA and P-CoA, and on specif
analogs, an amidic NH replaces a CH2 at position a and mimics substrate in form
react to (B).function describing the pre-transitional and post-transitional
portions of the unfolding trace. The fraction of the unfolded
protein, FD, at different temperatures is then given by:
FD ¼ ðh hNÞ=ðhU  hNÞ ð3Þ
The melting point, Tm, is the midpoint of transition where
hN = hU= 0.5. The Tm was calculated from FU-vs-T curve,
where Tm is the temperature at FD = 0.5. The data were
processed using the OriginR and KaleidaGraph programs.3. Results and discussion
3.1. Binding and interactions of ligands and substrates
Acyl-CoA dehydrogenases, and in particular MCAD, for
which the data are well documented [19], bind CoA con-
jugates very tightly, especially those that mimic structural
and/or chemical properties of substrate or product [20]. For
example: The Kd for binding of enoyl-CoA to reduced wt-
MCAD has been estimated to be of the order of 90 nM [21].
Several ACADs are isolated in a green form, where the color
is attributed to tightly bound CoA-S-persulfide, which
remains bound during the purification procedure [22]. Since
ligand binding affects stability, and as a basis for understand-
ing the effect of complex formation and change in redox state
on thermal unfolding and stability, we have addressed these
topics in some detail. It is important to note that the interac-
tion of ligands and substrates with ACADs is a complex
process [3], the salient components of which are shown in
Scheme 1. The complexation is relatively tight with a Kdc 5
AM, as is derived from plots of the absorbance changes at the
maxima of the difference spectra (Fig. 1, insert A). While the
pattern of the difference spectra (Fig. 1, insert B) is overall
similar to that reported by Thorpe’s group for MCAD [17],
there is a substantial difference: With i3VD there is a weak,ted from Refs. [3,25]. Step (a) is binding of ligand/substrate (S-CoA), and
complex (A). In the case of substrate step (b) follows, which reflects the
zyme with enoyl-CoA product (ACADredf P-CoA). This probably consists
blue color arising from a charge transfer interaction. Dissociation of product
), relatively slow [21], and leads to free P-CoA and free reduced enzyme
(P-CoA) can bind to free oxidized ACAD (step d). The reaction of substrate
equilibria, and wherein the relative concentrations of the components will
ic equilibrium constants. In the second type of species, 2-aza-CoA substrate
ing complex (A). However, due to the chemical modification, they do not
Fig. 1. Binding of the substrate analog 2-aza-iC5-CoA to wild-type i3VD. (Curve —) is the absorption spectrum of free enzyme, 18 AM in 50 mM Tris–Cl
buffer, pH 8.0 and at 25 jC. Curve (–o–) was obtained upon addition of a total of 72 AM of the ligand (corrected for dilution). Insert (B) shows selected
difference spectra obtained upon addition of (1) 2, 6, 16, 20, 46, 60 and (7) 96 AM of the ligand. Insert (A) depicts the changes at the indicated wavelengths as a
function of added ligand. The lines are the fits obtained with the mass equation.
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observable both in the main panel and in the difference
spectra which has a maximum around 510 nm (Fig. 1, panel
B). This is attributed to a charge transfer transition that is
typical for ACAD complexes involving a negatively charged
or electron-rich ligand and oxidized flavin cofactor [3].
However, 2-aza-iC5-CoA as such is not a donor; it becomes
one upon deprotonation of the 2-aza-function.
There are several examples of analogs that become
deprotonated at the a-position upon binding to MCAD,
two prominent ones being acetoacetyl-CoA and 3S-C8-CoA
[23,24]. The fact that the charge transfer intensity is weak
could be due to a low intrinsic extinction coefficient.
However, it is more probable that under the specific con-
ditions of Fig. 1, the equilibrium (pK) of Scheme 2. The
perturbation of the oxidized flavin spectrum is comparable
to that observed with wt-i3VD (compare difference spectraScheme 2. Mode of deprotonation of the 2-aza-iC5-CoA analog at the active
site of i3VD.in Figs. 1 and 2) suggesting that the binding modus is the
same. However, the binding constant Kd is one order of
magnitude higher. This can be attributed to the larger
volume of the valine isopropyl side chain compared to the
methyl of alanine. This volume increase would not allow as
tight a ‘‘closing’’ of the substrate binding cleft compared to
wt-i3VD.
Addition of substrate to ACADs leads to the setup of the
equilibria depicted in the Scheme 1 [3,25]. While the true
situation is more complex [21], this minimal scheme should
be adequate for the present case. The apparent binding
constant Kd,app deduced from the dependence of spectral
effects on the amount of added substrate will thus reflect all
involved steps, and in particular step (b), the internal redox
equilibrium of the system. In the case of wild-type MCAD,
Kd,app for the best substrate octanoyl-CoA can be estimated
as around 0.1–1 AM [21], and the prevalent species formed
with a small excesses of octanoyl-CoA is reduced enzyme
[26]. Kd,app is somewhat weaker for the K304E and T168A
mutants (Table 2) as can be deduced from the extent of
reduction of the oxidized enzymes [8,10].
The behavior observed with i3VD is qualitatively
similar. Addition of isovaleryl-CoA to i3VD leads to essen-
tially complete reduction of the oxidized enzyme flavin
with a Kd,appV 1 AM (Mohsen, A.W., and Vockley, J., in
preparation). This interaction is severely affected by the
Fig. 2. Interaction of A282V-i3VD with the substrate analogue 2-aza-iC5-CoA. General conditions as detailed in the legend of Fig. 1. Increasing amounts of the
ligand were added to the enzyme, the starting spectrum of which corresponds to Curve (1) in Fig. 3. The main panel depicts the difference spectra obtained
from subtraction of the initial spectrum from that at the given titration point. Only selected spectra are shown that correspond to addition of (1) = 8, (2) = 17,
(3) = 25, (4) = 33, (5) = 98, (6) 192, and (7) = 312 AM ligand (see insert for further titration points). All spectra and data points are corrected for dilution.
Analysis of the primary data was done with the global fitting program ‘‘Specfit-32’’ (that employs data points at all wavelengths) and the traces in the main
panel were obtained by a smoothing procedure of this program. The global procedure yields an apparent Kd = 36F 8 AM. The analysis in the insert is for the
two specific wavelengths shown and yields apparent Kds = 41F 9 (482 nm) and = 42F 13 AM (530 nm).
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Kd,app of the mutant for the substrate is approximately two
orders of magnitude higher and reduction occurs only to
c 60%. The latter can be deduced from the extent of
absorbance decrease in the 450 nm area that is due to
disappearance of the band of the oxidized flavin chromo-
phore (Fig. 3), and in comparison to wt-i3VD, where upon
incubation with excess substrate iC5-CoA removal of the
oxidized flavin absorbance is essentially complete (Mohsen,
A.W., and Vockley, J., in preparation). This behavior is
consistent with that found for the overall reaction using
the ETF reduction assay [14]. It implies that the substrate
binding step (Scheme 1, a) is also impaired as with the 2-
aza-analog, and that the internal redox equilibrium (Scheme
1, b) is not shifted completely to the right as with wt-i3VD.
3.2. Thermal unfolding of wild-type MCAD and wild-type
i3VD
Thermal unfolding of wt-MCAD was measured as a
function of temperature from 4 to 75 jC as shown in Fig.
4. The data show that denaturation of wt-MCAD depends on
its state of oxidation and on the presence of ligand. The
melting transition of the unliganded, oxidized wt-MCAD
enzyme is broad, extending from f 42 to f 60 jC anddisplaying a shoulder on the low-temperature side (Fig. 4,
insert). Differently, melting is much more sharp and sym-
metric in the presence of ligands. This suggests most likely
that the unliganded protein denatures through an intermedi-
ate. Addition of ligands apparently stabilizes the enzyme
and increases the cooperativity of thermal melting.
This behavior does not appear to apply for i3VD (Fig. 5),
since the first derivative profiles are comparatively sharp
and symmetric. Comparison of the data for the two enzymes
(Table 1) indicates that MCAD denatures at significantly
higher temperature than i3VD.
As discussed above, substrate leads to reduction of
ACADs and this is reflected by a stabilization corre-
sponding to an increase of the melting point by 6 (i3VD)
up to 10 jC (MCAD) (Table 2, Fig. 5). In the presence of
the substrate analog 2-aza-octanoyl-CoA that forms com-
plex (A) (Scheme 1) there is an increase by c 1–4 jC. The
differences in melting temperatures induced by the two
types of CoA (substrate vs substrate analog) thus reflect
the differences in interaction, respectively, with oxidized
and reduced MCAD, and indicate that the factors involving
the redox process are quantitatively more important than the
binding process for thermal stability.
Interestingly, with wt-MCAD the reaction with substrate
and 2-aza-ligand leads to a much sharper transition (Fig. 2,
Fig. 3. Interaction of A282V-i3VD with the substrate isovaleryl-CoA. The main panel depicts the spectral course of the anaerobic titration of the enzyme, c 20
AM in 50 mM Tris–HCl, pH 8.0 and at 25 jC with increasing aliquots of isovaleryl-CoA. Curve (1) is the spectrum of free enzyme, next curves to (5) are the
species that were obtained in the presence of c 5, 11, 21, 60 AM substrate. The inset shows the dependence of the spectral changes from the indicated
concentrations of added substrate recorded at wavelengths where they are maximal. The full lines are the fits obtained using the mass law equation and yield
‘‘interaction constants’’ (apparent Kds) of 30F 6 AM (446 nm) and 26F 6 AM (580 nm). The spectra and data points are corrected for dilution. See text for
further details.
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might exist in several conformers having marginally different
melting temperatures and is converted upon ligand binding
into single species corresponding to (A) or (B), respectively;
Scheme 1. Comparison of the same phenomena for MCAD
and i3VD uncovers greater stabilization by substrate for
MCAD compared to i3VD (7–10 vs c 6 jC, Table 2).
3.3. Effect of genetic mutations on thermal stability
In previous experiments the activity of the K304E and
T168A mutants were compared to that of wt-MCAD by
assessing the activity upon a definite time of incubation at
different temperatures [8,10]. It was estimated that the
activity decreases to 50% of the maximal value at c 52
and c 41 jC for the K304E and T168A-MCAD mutants,
respectively. The latter was completely inactivated after 20-
min incubation at 41 jC [10]. However, this type of
experiments does not take into account the effect of
ligands/substrate and constitutes only a rather crude esti-
mate. This is of importance since ligation and the redox state
have pronounced effects on the stability of ACADs [27]. We
have examined this directly with thermal denaturation
experiments (Fig. 6).
The K304E-MCAD mutant was found to unfold atc 3.5
jC lower than wt-enzyme. However, the K304E mutantprotein responds to the presence/addition of the substrate
octanoyl-CoA in a very similar way, the stabilizing effect is
thus similar for both proteins (Table 2) consistent with an
analogous thermodynamic effect accompanying formation
of reduced enzyme. From this it can be concluded that,
under physiological conditions, thermal instability is not a
major factor responsible for the observed clinical effects.
Previous studies had concluded that the mutation mainly
affected the ‘‘conformation’’ of the K304E-MCAD protein
[28] in addition to its capacity to be expressed in a soluble,
active form [29], and to effects on its catalytic properties/
specificity [8]. The data presented here clearly support the
importance of these factors. In contrast to the K304E
mutant, the T168A-MCAD variant has a greatly reduced
thermal stability both as a free protein, as well as in the
presence of a substrate or substrate analog (Table 2). The
extent of thermal destabilization induced by the T to A
replacement suggests that it is a (major) source for protein
instability in vivo and hence a molecular cause for the
observed clinical symptoms.
3.4. Comparison of the data with structural information
The present results provide a semiquantitative picture of
the factors that affect unfolding of two of the best-studied
members of the ACAD family, MCAD and i3VD. They also
Fig. 5. Thermal unfolding curves of wt-i3VD. Main panel: (1) in the absence of substrate, (2) in the presence of 20 AM iC5CoA, and (3) in the presence of 20
AM 2-aza-iC5CoA. Normalization and conditions as in Fig. 4. Insert: First derivative of the CD spectra for curves (1) and (2).
Fig. 4. Thermal unfolding curves of wt-MCAD. Main panel: (1) in the absence of substrate; (2) in the presence of 20 AM 2-aza-C8CoA; (3 and 4) in the
presence of 20 and 300 AM C8CoA. The spectra were normalized for the values of intact proteins and changes were followed by far-UV CD at k222 nm.
Conditions are detailed in Materials and methods. Insert: First derivative of the CD spectra for curves (1) and (3).
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Table 2
Apparent melting points of MCAD, i3VD and of mutants and effect of substrate or ligand binding
Enzyme, form Substrate/ligand Tm/jC Substrate/ligand (apparent) Kd
Structure Concentration/AM
MCAD Wild-type, ox None 56.4 –
ox/red C8-CoA, 20 63.5 0.1–1 AM [17]
red C8-CoA, 300 66.9
ox 2-aza-C8-CoA 20 59.3 0.05 AM [17]
K304E, ox None 53 –
ox/red C8-CoA 20 60 z 1 AM (a)
red C8-CoA 300 64
ox 2-aza-C8-CoA 20 59.1 c 0.5 AM
T168A, ox None 46.7 –
ox/red C8-CoA 20 52.5 z 1 AM (a)
red C8-CoA 300 58.1
ox 2-aza-C8-CoA 20 52.1 nd
i3VD Wild-type, ox None 50.5 –
ox/red iV-CoA 20 55.4 = 1 AM (b)
ox 2-aza-iC5-CoA 20 50.9 c 5 AM
A282V, ox None 48.2 –
ox/red iV-CoA 20 48.5 c 30 AM
ox 2-aza-iC5-CoA 20 48.6 c 40 AM
The abbreviations ox, red and ox/red stand for oxidized, reduced, or a mixture of these species; iV= isovaleryl. (a) As explained in the text this value is a rough
estimate that reflects the equilibrium situation described by Scheme 1. (b) Mohsen, W. and Vockley, J., unpublished data.
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of genetically determined mutations affecting ACADs.
Comparison of the melting temperatures for the various
forms of MCAD and i3VD (Table 2, Figs. 4–6) suggests
that the thermal stability of wild-type MCAD is rather high
compared to that of i3VD; a difference of 6 jC in the
melting temperature is significant. The overall supersecon-Fig. 6. Thermal unfolding curves of K304E-MCAD. Main panel: (1) in the absenc
presence of 20 and 300 AM C8CoA. Normalization and conditions as in Fig. 4. Idary or quaternary structures of the two enzymes are very
similar, with the exception of a disulfide bond between
Cys318 and Cys323 in the loop connecting a-helices H and
I present in i3VD [13]. A specific reason for this difference
is thus not evident. On the other hand, it should be kept in
mind that FAD binding/affinity is important in protein
stability [30]. While there are no quantitative data on thee of substrate; (2) in the presence of 20 AM 2-aza-C8CoA; (3 and 4) in the
nsert: First derivative of the normalized CD spectra for curves (1) and (3).
Fig. 7. Three-dimensional representation of the location of the K304E-
mutation in MCAD. Helices (I), (H) belong to a different subunit than (K).
They are part of the interface domain of homotetrameric MCAD. It should
be noted that the K304E-mutation will affect the balance of charges of the
D346, K304, D300 and R383 groups and consequently is likely to influence
their reciprocal positioning/orientation.
Fig. 8. Position of A282 in i3VD relative to the cofactor FAD. This group is
located near the interface of two subunits of the homotetrameric enzyme
and in close proximity to the adenylate moiety of FAD. In the A282V
mutant the larger size of the valine side chain is likely to ‘‘force open’’ the
cleft serving for the binding of the FAD AMP moiety. (The prime sign
denotes ligand or residue of the second subunit). Adapted from Ref. [13].
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evidence suggests that FAD affinity is lower in the case of
i3VD. As an example, T168-OH forms a tight H-bond to the
flavin N-5 position both in MCAD and i3VD [6]; its
removal as with the T168A-MCAD mutant greatly reduces
the affinity for FAD [10]. While the T168A-MCAD mutant
is produced in E. coli, and can be purified, if FAD is present
in buffers during purification, this is not the case with the
corresponding T168A-i3VD mutant (Mohsen, A.W. and
Vockley, J., unpublished). This is consistent with a signif-
icantly weaker FAD binding of wt-i3VD that translates into
a lower stability, and with a further weakening in the case of
the A282V-i3VD mutant. In a general sense, it appears that
thermal stability is substantially lower in i3VDs compared
to MCAD, the same holding for the corresponding mutants
(Table 2).
The –OH group of T168 in MCAD is positioned exactly
in the projection of the flavin plane, and forms a tight H-
bond (2.9 A˚) with the flavin N(5), the entry point for
hydride during catalysis. An identical situation is found in
i3VD [13]. A specific role for such an H-bond also is
probable since the activity of the mutant is substantially
reduced [10]. It is known [24] that for wt-MCAD the pK for
the abstraction of a CoA ligand aC-H is lowered by z 10
pK units at the active center. With T168A-MCAD the pK
shift is much smaller (V 5 pK units, R. Gradinaru and S.
Ghisla, unpublished data) corresponding to a difference of
c 7 kcal/mol. This is corroborated by the observation of a
similar effect with wt-MCAD in which the native FADcofactor has been replaced by its 5-deaza-FAD analog
(Gradinaru and S. Ghisla, unpublished data). Deaza flavins
cannot form such H-bonds. In addition, the Thr168-OH
might also serve in the fixation/positioning of the flavin
[6,10] and thus indirectly affect the stability of the protein
[30]. In the context of enzyme stability, it thus appears that
this simple H-bond might be unusually important as
reflected by the large effect on enzyme thermal unfolding.
Along this line of reasoning, it can be deduced that the
substantially modified activity vs. chain length profile
exhibited by T168A-MCAD compared to wt enzyme [10]
is due to enhanced flexibility at the active center.
The effect of genetic mutations on protein melting points
is best represented by the K304E-MCAD case. Previous
studies had concluded that the mutation mainly affected the
‘‘conformation’’ of the enzyme [28] in addition to its
capacity to be expressed in a soluble, active form [29],
and to effects on its catalytic properties and the chain length
specificity [8]. While the melting behavior confirms the
diminished stability of this protein, the observed effect is
comparatively small. Interestingly, substrate binding
restores the thermal stability of the K304E mutant protein
approximately to the level of wild-type enzyme. Inspection
of the dimer–dimer interface domain of MCAD that is part
of the homotetrameric native structure (Fig. 7) shows that
K304 is part of a quaternary interaction of the groups R383,
D300, K304 and D346 located on helices J, H and K (Fig.
7). Hence, it is probable that a K304E mutation affects the
strength of the salt bridge between D300 and R383 (Fig. 7)
and that this, in turn, affects the tertiary/quaternary structure.
Turning to i3VD, the lack of substantial changes in the
melting temperature of the genetic A282V mutant in the
I. Nasser et al. / Biochimica et Biophysica Acta 1690 (2004) 22–32 31presence of ligand and substrate, and as compared to wt-
i3VD, is relevant. This is consistent with the mutant having
substantially weaker affinities for ligands (Table 2) and also
a c 35-fold lower activity [14]. Also in this case the
A282V mutation is considerably distant from the active
centers, of the same subunit (c 41 A˚) or the neighboring
subunit (c 17 A˚). It is, however, in close proximity to
residues constituting the FADV adenine binding cleft (the
prime sign denotes ligand or residue of the second subunit).
Fig. 8 shows that it is located at the monomer–monomer
interface near the amino acid side chains of F290 that are in
contact with the adenosyl moiety of FAD. In addition, F283,
which would be above the plane of the figure, is 3.5 A˚ away
from the Ch of the A282 and 3.2 A˚ away from the FADV
adenine, apparently providing k–k interaction to the latter.
Examination of the arrangements in Fig. 8 suggests that
replacement of alanine with a valine would affect binding
of FAD by disrupting the interactions of its AMP moiety
with the above residues. This, in turn, might affect the
interactions of S142V with the adenosyl moiety of FAD
and the pantetheine moiety of the CoA ligand and conse-
quently impair binding of the latter. Another possible
effect for the A282V replacement is that the valine side
chain in the mutant would force the side chain of F283,
which is 4 A˚ away from the phosphate of the AMPV
moiety of the i3V-CoAV in the published model [13], to
adopt a slightly different conformation bringing it closer to
this possibly charged phosphate and hence disrupting
substrate binding.
It has been difficult to show genotype/phenotype corre-
lations for mutations identified in patients with MCAD
deficiency. Heterogeneous symptoms have been reported
in patients with the common K304E mutation as well as in
others seen in more than one patient. The present data
substantiate the assumption that with this mutant thermal
instability as such is not a major factor in disease manifes-
tation, as opposed to the effects on efficiency of de novo
folding. With the T168A mutation, however, thermal insta-
bility of the already processed and folded protein is much
more pronounced arguing that it is a major molecular cause
for the observed symptoms. Patients having i3VD mutations
that lead to an enzyme with partially reduced activity and/or
stability tend to have milder clinical symptoms than those
with mutations leading to lack of enzyme protein at the
cellular level. In such cases, reduced thermal stability of a
mutant enzyme may play a role in the development of
symptoms during times of illness, especially those associ-
ated with fever. Study of additional patients and mutations
will be necessary to substantiate this.Acknowledgements
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